Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles
NCT03181685 · Andros Day Surgery Clinic · PHASE4 · terminated · last registry update 2020-01-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “27 couples were recruited. This unexpected poor recruitment was due to more clinical pregnancies (for a better patients' selection) and more freeze-all cycles.” | – | Registry record, Andros Day Surgery Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-24Results posted on the registry: University of Colorado, Denver, a drug against PGR (NCT04005391)
- 2020-11-18Results posted on the registry: Lisa Haddad, Depot medroxyprogesterone acetate (DMPA) (NCT02357368)
- 2020-11-09Results posted on the registry: Boehringer Ingelheim, Microgynon + Nintedanib (NCT03675581)
- 2020-10-19Also stopped (terminated): Check, Jerome H., M.D., Ph.D., Mifepristone (NCT02642939)
- 2020-10-06Phase 3 first posted: Geron Corporation, Imetelstat + Best Available Therapy (BAT) (NCT04576156)
- 2020-09-25Results posted on the registry: Peking University People's Hospital, Berberine plus danazol (NCT03909763)
- 2020-09-02Results posted on the registry: Gilead Sciences, SOF/VEL/VOX + VOX (NCT02533427)
- 2020-08-27Results posted on the registry: ViiV Healthcare, GSK3640254 + Portia (NCT03984825)
- 2020-08-26Phase 3 first posted: Milton S. Hershey Medical Center, Cannabidiol (CBD) Extract + Norethindrone Acetate (NCT04527003)
- 2020-08-13Also stopped (withdrawn): Istanbul Training and Research Hospital, YASMIN® (Drospirenone/Ethinyl Estradiol) (NCT01805817)
- 2020-07-15Results posted on the registry: AbbVie (prior sponsor, Abbott), Elagolix + Placebo (NCT01441635)
- 2020-07-07Phase 3 first posted: Sebela Women's Health Inc., LevoCept (NCT04457076)
- 2020-06-30Results posted on the registry: AbbVie, Elagolix + Placebo for Estradiol/Norethindrone Acetate (NCT02691494)
- 2020-06-30Results posted on the registry: AbbVie, Estradiol/Norethindrone Acetate + Elagolix (NCT02925494)
- 2020-05-13Phase 3 first posted: Zagazig University, Oral Megesterol 160 mg daily (NCT04385667)
- 2020-04-09Phase 3 first posted: Cairo University, vaginal misoprostol + Lidocaine-Prilocaine Topical cream (NCT04339348)
- 2020-03-18Results posted on the registry: Massachusetts General Hospital, Transdermal 17Beta-estradiol, progesterone + Ethinyl Estradiol + Desogestrel (NCT00946192)
- 2019-12-05Results posted on the registry: Organon and Co, Nomegestrol acetate (NOMAC) + Etonogestrel (ENG) (NCT01709318)
- 2019-11-22Phase 3 first posted: Sierra Oncology LLC - a GSK company, Momelotinib + Placebo to match danazol (NCT04173494)
- 2019-10-02Phase 3 first posted: HRA Pharma, Norgestrel 0.075 mg tablets (NCT04112095)
- 2019-07-05Phase 3 first posted: Leiden University Medical Center, Ethinylestradiol/levonorgestrel + Vitamin E (NCT04007874)
- 2019-05-31Phase 3 first posted: Milton S. Hershey Medical Center, Naltrexone + Norethindrone Acetate (NCT03970330)
- 2019-03-29Phase 3 first posted: Centre Hospitalier Intercommunal Creteil, Desogestrel early follicular phase + Desogestrel medium follicular phase (NCT03895099)
- 2019-03-18Results posted on the registry: Washington University School of Medicine, Mifepristone (NCT01333098)
- 2019-01-18Results posted on the registry: Organon and Co, ENG-E2 125 μg/300 μg vaginal ring + LNG-EE 150 μg/30 μg COC (NCT02616146)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision